Clinical Center; Notice of Meeting, 10770 [07-1099]
Download as PDF
<![CDATA[
10770
Federal Register / Vol. 72, No. 46 / Friday, March 9, 2007 / Notices
jlentini on PROD1PC65 with NOTICES
combination with irradiated CT26 cells
enhances tumor regression in another
mouse model. The investigators found
that administering the combination of
agents is more effective than the sum of
their individual effects.
Applications: A method of cancer
combination therapy based on
immunotherapeutics.
Development Status: The invention is
in the clinical stages of development.
Inventors: Masaki Terabe (NCI) et al.
Publications:
1. PCT patent publication WO 2006/
089251, August 24, 2006.
2. M Terabe et al. Transforming
growth factor-beta production and
myeloid cells are an effector mechanism
through which CD1d-restricted T cells
block cytotoxic T lymphocyte-mediated
tumor immunosurveillance: abrogation
prevents tumor recurrence. J Exp Med.
2003 Dec 1;198(11):1741–1752.
Patent Status: U.S. Provisional
Application No. 60/654,329 filed 17 Feb
2005 (HHS Reference No. E–019–2005/
0–US–01); PCT Application No. PCT/
US2006/005888 filed 16 Feb 2006 (HHS
Reference No. E–019–2005/0–PCT–02).
Licensing Availability: Available for
exclusive and non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov
Arylthioindole Tubulin Polymerization
Inhibitors and Methods of Treating or
Preventing Cancer Using Same
Description of Technology:
Microtubules are involved in a variety
of cellular functions including motility,
division, shape maintenance, and
intracellular transport. Tubulin is the
major protein component in
microtubules, and interference with
microtubule assembly leads to an
increase of cells in metaphase arrest.
Inhibition of microtubule function using
tubulin targeted agents are widely used
in the treatment of cancer.
This invention describes novel
arylthioindole derivatives, 3arylthioindole-2-carboxylic acid esters
derivatives, having excellent affinity for
tubulin and excellent efficacy as
inhibitors of the growth of MCF–7 breast
cancer cells. These new chemical
compounds have the potential to result
in more effective therapeutics for the
treatment of neoplastic diseases.
Applications: Therapeutic for
proliferative diseases such as cancer.
Market: 600,000 deaths from cancer
related diseases estimated in 2006.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Ernest Hamel (NCI) et al.
Publications:
1. G De Martino, MC Edler, G La
Regina, A Coluccia, MC Barbera, D
VerDate Aug<31>2005
21:24 Mar 08, 2007
Jkt 211001
Barrow, RI Nicholson, G Chiosis, A
Brancale, E Hamel, M Artico, R
Silvestri. New arylthioindoles: potent
inhibitors of tubulin polymerization. 2.
Structure-activity relationship and
molecular modeling studies. J Med
Chem. 2006 Feb 9;49(3):947–954.
2. G De Martino, G La Regina, A
Coluccia, MC Edler, MC Barbera, A
Brancale, E Wilcox, E Hamel, M Artico,
R Silvestri. Arylthioindoles, potent
inhibitors of tubulin polymerization. J
Med Chem. 2004 Dec 2;47(25):6120–
6123.
Patent Status: PCT Application No.
PCT/US2005/035896 filed 05 Oct 2005
(HHS Reference No. E–323–2004/0–
PCT–02).
Licensing Availability: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Dated: March 2, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–4182 Filed 3–8–07; 8:45 am]
Any interested person may file written
comments with the committee by forwarding
the statements to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Dated: March 2, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1099 Filed 3–8–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4140–01–P
National Cancer Institute; Amended
Notice of Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice is hereby given of a change in
the meeting of the President’s Cancer
Panel, February 12, 2007, 8 a.m. to
February 12, 2007, 6 p.m., University of
Mississippi, Medical Center, 2500 North
State Street, Jackson, MS 39216 which
was published in the Federal Register
on January 11, 2007, 72 FR 1335.
Due to inclement weather, this
meeting is amended to reschedule the
closed session on February 12, 2007, 4
p.m.–6 p.m. to March 8, 2007, 11 a.m.–
1 p.m. as a telephone conference. The
meeting is closed to the public.
National Institutes of Health
Clinical Center; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the NIH
Advisory Board for Clinical Research.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: NIH Advisory Board
for Clinical Research.
Date: March 23, 2007.
Time: 10 a.m. to 2 p.m.
Agenda: To discuss progress of activities
related to research opportunities, training,
planning and funding in the NIH intramural
clinical research program.
Place: National Institutes of Health,
Building 10, 10 Center Drive, CRC Medical
Board Room 4–2551, Bethesda, MD 20892.
Contact Person: Maureen E. Gormley,
Executive Secretary, Mark O. Hatfield
Clinical Research Center, National Institutes
of Health, Building 10, Room 6–2551,
Bethesda, MD 20892, 301/496–2897.
This notice is being published less than 15
days prior to the meeting due to the urgent
need to meet timing limitations imposed by
the intramural research review cycle.
PO 00000
Frm 00141
Fmt 4703
Sfmt 4703
Dated: March 5, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1109 Filed 3–8–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\09MRN1.SGM
09MRN1
]]>Agencies
[Federal Register Volume 72, Number 46 (Friday, March 9, 2007)]
[Notices]
[Page 10770]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1099]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the NIH Advisory Board for Clinical Research.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: NIH Advisory Board for Clinical Research.
Date: March 23, 2007.
Time: 10 a.m. to 2 p.m.
Agenda: To discuss progress of activities related to research
opportunities, training, planning and funding in the NIH intramural
clinical research program.
Place: National Institutes of Health, Building 10, 10 Center
Drive, CRC Medical Board Room 4-2551, Bethesda, MD 20892.
Contact Person: Maureen E. Gormley, Executive Secretary, Mark O.
Hatfield Clinical Research Center, National Institutes of Health,
Building 10, Room 6-2551, Bethesda, MD 20892, 301/496-2897.
This notice is being published less than 15 days prior to the
meeting due to the urgent need to meet timing limitations imposed by
the intramural research review cycle.
Any interested person may file written comments with the
committee by forwarding the statements to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Dated: March 2, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-1099 Filed 3-8-07; 8:45 am]
BILLING CODE 4140-01-M
